{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:51:13Z","timestamp":1767862273411,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T00:00:00Z","timestamp":1204588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title><jats:sc>Summary<\/jats:sc><\/jats:title><jats:p> <jats:bold>\n            <jats:styled-content>Purpose:<\/jats:styled-content> To evaluate the anticonvulsant profile and behavioral toxicity of rufinamide in animal seizure models compared to the established antiepileptic drugs (AEDs): phenytoin, phenobarbital, valproate, and ethosuximide, or vehicle.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Methods:<\/jats:styled-content> In acute studies of anticonvulsant efficacy, the AEDs were administered via oral (CF1 mice and Sprague\u2013Dawley rats) and intraperitoneal (CF1 mice) routes. The AEDs were assessed for their ability to inhibit seizures induced by maximal electroshock (MES) or subcutaneous pentylenetetrazol, and ability to block seizures induced by subcutaneous strychnine, bicuculline, or picrotoxin. Tolerance of oral rufinamide was assessed in rats following 5\u2010day (versus single\u2010dose) treatment with oral rufinamide using the dose equivalent necessary to achieve a 50% decrease in seizure frequency (ED<jats:sub>50<\/jats:sub>). Metabolic tolerance was also evaluated using an in vitro liver microsomal assay.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Results:<\/jats:styled-content> Oral rufinamide suppressed pentylenetetrazol\u2010induced seizures in mice (ED<jats:sub>50<\/jats:sub> 45.8 mg\/kg) but not rats, and was active against MES\u2010induced tonic seizures in mice (ED<jats:sub>50<\/jats:sub> 23.9 mg\/kg) and rats (ED<jats:sub>50<\/jats:sub> 6.1 mg\/kg). Intraperitoneal rufinamide suppressed pentylenetetrazol\u2010, bicuculline\u2010, and picrotoxin\u2010induced clonus in mice (ED<jats:sub>50<\/jats:sub> 54.0, 50.5, and 76.3 mg\/kg, respectively). Rufinamide was partially effective in the mouse strychnine test. The behavioral toxicity of rufinamide was similar to or better than established AEDs tested in this study. In general, the protective index of rufinamide was greater than that of the other AEDs.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>\n            <jats:styled-content>Conclusions:<\/jats:styled-content> The efficacy and behavioral toxicity profiles in these animal models suggest that rufinamide may be effective in the treatment of generalized and partial seizures.<\/jats:bold> <\/jats:p>","DOI":"10.1111\/j.1528-1167.2008.01552.x","type":"journal-article","created":{"date-parts":[[2008,3,4]],"date-time":"2008-03-04T23:07:53Z","timestamp":1204672073000},"page":"1213-1220","source":"Crossref","is-referenced-by-count":64,"title":["The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models"],"prefix":"10.1111","volume":"49","author":[{"given":"H. Steve","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey J.","family":"Kupferberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Stables","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold H.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030460322"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1636052"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(71)90213-X"},{"key":"e_1_2_6_5_1","first-page":"1417","volume-title":"Epilepsy: a comprehensive textbook","author":"Kupferberg HJ","year":"1998"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00607.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00016-3"},{"issue":"6","key":"e_1_2_6_8_1","first-page":"375","article-title":"The influence of rufinamide on sodium currents and action potential firing in rodent neurons","volume":"46","author":"McLean MJ","year":"2005","journal-title":"Epilepsia"},{"key":"e_1_2_6_9_1","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"1996"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(72)90177-0"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02029.x"},{"key":"e_1_2_6_12_1","first-page":"223","article-title":"Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds","volume":"42","author":"Rogawski MA","year":"1990","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178973"},{"issue":"2","key":"e_1_2_6_14_1","first-page":"S122","article-title":"Anticonvulsant profile of CGP 33101 in animals","volume":"34","author":"Schmutz M","year":"1993","journal-title":"Epilepsia"},{"key":"e_1_2_6_15_1","first-page":"7","article-title":"Pharmacological models of generalized absence seizures in rodents","volume":"35","author":"Snead OC","year":"1992","journal-title":"J Neural Transm Suppl"},{"key":"e_1_2_6_16_1","unstructured":"StablesJP KupferbergJK. (2005)The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. Accessed viahttp:\/\/www.ninds.nih.gov\/funding\/research\/asp\/addadd_review.pdfon December 12 2006."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(93)90007-T"},{"key":"e_1_2_6_18_1","first-page":"99","volume-title":"Antiepileptic Drugs","author":"White HS","year":"1995"},{"key":"e_1_2_6_19_1","first-page":"36","volume-title":"Antiepileptic Drugs","author":"White HS","year":"2002"},{"key":"e_1_2_6_20_1","first-page":"97","article-title":"Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern","volume":"92","author":"Woodbury LA","year":"1952","journal-title":"Arch Int Pharmacodyn Ther"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01552.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01552.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:42:09Z","timestamp":1697334129000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01552.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01552.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01552.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}